<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Some reported causes and potentiators of the long QT syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Some reported causes and potentiators of the long QT syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Some reported causes and potentiators of the long QT syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1_single" colspan="4">Congenital</td> </tr> <tr class="border_bottom_thick"> <td colspan="4"> <ul class="decimal_heading"> <li>Jervell and Lange-Nielsen syndrome (including "channelopathies")</li> <li>Romano-Ward syndrome</li> <li>Idiopathic</li> </ul> </td> </tr> <tr> <td class="subtitle1_single" colspan="4">Acquired</td> </tr> <tr> <td><strong>Metabolic disorders</strong> <ul class="decimal_heading"> <li>Hypokalemia</li> <li>Hypomagnesemia</li> <li>Hypocalcemia</li> <li>Starvation</li> <li>Anorexia nervosa</li> <li>Liquid protein diets</li> <li>Hypothyroidism</li> </ul> <p class="extra_spacing_top"><strong>Bradyarrhythmias</strong></p> <ul class="decimal_heading"> <li>Sinus node dysfunction</li> <li>AV block: Second or third degree</li> </ul> </td> <td><strong>Other factors</strong> <ul class="decimal_heading"> <li>Myocardial ischemia or infarction, especially with prominent T-wave inversions</li> <li>Intracranial disease</li> <li>HIV infection</li> <li>Hypothermia</li> <li>Toxic exposure: Organophosphate insecticides</li> </ul> </td> <td colspan="2"><strong>Androgen deprivation therapy</strong> <ul class="decimal_heading"> <li>GnRH agonist/antagonist therapy</li> <li>Bilateral surgical orchiectomy</li> </ul> <p class="extra_spacing"><strong>Diuretic therapy</strong> via electrolyte disorders particularly hypokalemia and hypomagnesemia</p> <strong>Herbs</strong> <ul class="decimal_heading"> <li>Cinchona (contains quinine), iboga (ibogaine), licorice extract in overuse via electrolyte disturbances</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Medications<sup>*</sup></td> </tr> <tr> <td class="subtitle3_left_align" colspan="4">High risk</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Adagrasib</li> <li>Ajmaline<sup>¶</sup></li> <li>Amiodarone<sup>Δ</sup></li> <li>Arsenic trioxide</li> <li>Astemizole<sup>◊</sup></li> <li>Bedaquline</li> <li>Bepridil<sup>◊</sup></li> <li>Chlorpromazine</li> </ul> </td> <td> <ul> <li>Cisaparide (restricted availability)</li> <li>Delamanid<sup>¶</sup></li> <li>Disopyramide<sup>Δ</sup></li> <li>Dofetilide</li> <li>Dronedarone</li> <li>Haloperidol (IV)</li> <li>Ibutilide</li> <li>Ivosidenib</li> </ul> </td> <td> <ul> <li>Lenvatinib</li> <li>Levoketoconazole</li> <li>Methadone</li> <li>Mobocertinib</li> <li>Papavirine (intracoronary)</li> <li>Procainamide</li> <li>Quinidine</li> <li>Quinine</li> </ul> </td> <td> <ul> <li>Selpercatinib</li> <li>Sertindole<sup>¶</sup></li> <li>Sotalol</li> <li>Terfenadine<sup>◊</sup></li> <li>Vandetanib</li> <li>Vernakalant<sup>¶</sup></li> <li>Ziprasidone</li> </ul> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="4">Moderate risk</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Amisulpride<sup>¶</sup> (oral)<sup>§</sup></li> <li>Azithromycin</li> <li>Capecitabine</li> <li>Carbetocin<sup>¶</sup></li> <li>Certinib</li> <li>Chloroquine</li> <li>Citalopram</li> <li>Clarithromycin</li> <li>Clofazimine</li> <li>Clomipramine<sup>¥</sup></li> <li>Clozapine</li> <li>Crizotinib</li> <li>Dabrafenib</li> <li>Dasatinib</li> <li>Deslurane</li> <li>Domperidone<sup>¶</sup></li> <li>Doxepin<sup>¥</sup></li> <li>Doxifluridine<sup>¶</sup></li> </ul> </td> <td> <ul> <li>Droperidol</li> <li>Encorafenib</li> <li>Entrectinib</li> <li>Erythromycin</li> <li>Escitalopram</li> <li>Etelcalcetide</li> <li>Fexinidazole</li> <li>Flecainide</li> <li>Floxuridine</li> <li>Fluconazole</li> <li>Fluorouracil (systemic)</li> <li>Flupentixol<sup>¶</sup></li> <li>Gabobenate dimeglumine</li> <li>Gemifloxacin<sup>¶</sup></li> <li>Gilteritinib</li> <li>Halofantrine</li> <li>Haloperidol (oral)</li> <li>Imipramine<sup>¥</sup></li> </ul> </td> <td> <ul> <li>Inotuzumab ozogamacin</li> <li>Isoflurane</li> <li>Levetiracetam</li> <li>Levofloxacin (systemic)</li> <li>Lofexidine</li> <li>Meglumine antimoniate</li> <li>Midostaurin</li> <li>Moxifloxacin</li> <li>Nilotinib</li> <li>Olanzapine</li> <li>Ondansetron (IV &gt; oral)</li> <li>Osimertinib</li> <li>Oxytocin</li> <li>Pazopanib</li> <li>Pentamidine</li> <li>Pilsicainide<sup>◊</sup></li> <li>Pimozide</li> <li>Piperaquine</li> <li>Probucol<sup>◊</sup></li> </ul> </td> <td> <ul> <li>Propafenone</li> <li>Propofol</li> <li>Quetiapine</li> <li>Quizartinib</li> <li>Ribociclib</li> <li>Risperidone</li> <li>Saquinavir</li> <li>Sevoflurane</li> <li>Sparfloxacin<sup>¶</sup></li> <li>Sunitinib</li> <li>Tegafur<sup>¶</sup></li> <li>Terbutaline</li> <li>Thioridazine</li> <li>Toremifene</li> <li>Vemurafenib</li> <li>Voriconazole</li> </ul> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="4">Low risk<sup>‡</sup></td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Albuterol</li> <li>Alfuzosin</li> <li>Amisulpride (IV)<sup>§</sup></li> <li>Amitriptyline<sup>¥</sup></li> <li>Anagrelide</li> <li>Apomorphine</li> <li>Arformoterol</li> <li>Artemether-lumefantrine</li> <li>Asenapine</li> <li>Atomoxetine</li> <li>Benperidol</li> <li>Bilastine<sup>¶</sup></li> <li>Bosutinib</li> <li>Bromperidol</li> <li>Buprenorphine<sup>†</sup></li> <li>Buserelin</li> <li>Ciprofloxacin (Systemic)</li> <li>Cocaine (Topical)</li> <li>Degarelix</li> <li>Desipramine<sup>¥</sup></li> <li>Deutetrabenazine</li> <li>Dexmedetomidine<sup>**</sup></li> <li>Dolasetron</li> <li>Donepezil</li> <li>Efavirenz</li> <li>Eliglustat</li> <li>Eribulin</li> <li>Etrasimod</li> </ul> </td> <td> <ul> <li>Ezogabine</li> <li>Fingolimod</li> <li>Fluoxetine</li> <li>Fluphenazine</li> <li>Formoterol</li> <li>Foscarnet</li> <li>Fostemsavir</li> <li>Gadofosveset</li> <li>Gepirone</li> <li>Glasdegib</li> <li>Goserelin</li> <li>Granisetron</li> <li>Hydroxychloroquine (rare reports)</li> <li>Hydroxyzine</li> <li>Iloperidone</li> <li>Indacaterol</li> <li>Itraconazole</li> <li>Ketoconazole (systemic)</li> <li>Lacidipine</li> <li>Lapatinib</li> <li>Lefamulin</li> <li>Leuprolide</li> <li>Leuprolide-norethindrone</li> <li>Levalbuterol</li> <li>Levomethadone</li> <li>Lithium</li> <li>Loperamide<sup>¶¶</sup> in overdose</li> <li>Lopinavir</li> </ul> </td> <td> <ul> <li>Macimorelin</li> <li>Mefloquine</li> <li>Mequitazine</li> <li>Methotrimeprazine</li> <li>Metoclopramide (rare reports)</li> <li>Metronidazole (systemic)</li> <li>Mifepristone</li> <li>Mirtazapine</li> <li>Mizolastine</li> <li>Nelfinavir</li> <li>Norfloxacin</li> <li>Nortriptyline<sup>¥</sup></li> <li>Ofloxacin (systemic)</li> <li>Olodaterol</li> <li>Osilodrostat</li> <li>Oxaliplatin</li> <li>Ozanimod<sup>ΔΔ</sup></li> <li>Pacritinib</li> <li>Paliperidone</li> <li>Panobinostat</li> <li>Pasireotide</li> <li>Pefloxacin</li> <li>Periciazine<sup>¶</sup></li> <li>Pimavanserin</li> <li>Pipamperone</li> <li>Pitolisant</li> <li>Ponesimod</li> <li>Primaquine</li> </ul> </td> <td> <ul> <li>Promazine</li> <li>Radotinib</li> <li>Ranolazine (due to bradycardia)</li> <li>Relugolix</li> <li>Rilpivirine</li> <li>Romidepsin</li> <li>Roxithromycin</li> <li>Salmeterol</li> <li>Sertraline</li> <li>Siponimod</li> <li>Solifenacin</li> <li>Sorafenib</li> <li>Sulpiride</li> <li>Tacrolimus (systemic)</li> <li>Tamoxifen</li> <li>Telavancin</li> <li>Teneligliptin</li> <li>Tetrabenazine</li> <li>Trazodone</li> <li>Triclabendazole</li> <li>Triptorelin</li> <li>Tropisetron<sup>¶</sup></li> <li>Vardenafil</li> <li>Vilanterol</li> <li>Vinflunine</li> <li>Voclosporin</li> <li>Vorinostat</li> <li>Zuclopenthixol</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This is not a complete list of all corrected QT interval (QTc)-prolonging drugs and does not include drugs with either a minor degree or isolated association(s) with QTc prolongation that appear to be safe in most patients but may need to be avoided in patients with congenital long QT syndrome depending upon clinical circumstances. A more complete list of such drugs is available at the <a href="https://crediblemeds.org/" target="_blank">CredibleMeds</a> website. For clinical use and precautions related to medications and drug interactions, refer to the UpToDate topic review of acquired long QT syndrome discussion of medications and the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> tool.</div><div class="graphic_footnotes"><p>AV: atrioventricular; IV: intravenous; QTc: rate-corrected QT interval on the electrocardiogram.</p>
<p>* Classifications provided by Lexicomp according to US Food &amp; Drug Administration guidance: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythic Potential for Non-Antiarrhythmic Drugs – Questions and Answers; Guidance for Industry US Food and Drug Administration, June 2017 (revision 2) available at: <a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf" target="_blank">https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf</a> as updated August 8, 2023 (<a href="https://www.fda.gov/media/170814/download" target="_blank">https://www.fda.gov/media/170814/download</a>) with additional data from CredibleMeds QT drugs list<sup>[1,2]</sup>. The use of other classification criteria may lead to some agents being classified differently by other sources.</p>
<p>¶ Not available in the United States.</p>
<p>Δ In contrast with other class III antiarrhythmic drugs, amiodarone is rarely associated with torsades de pointes; refer to accompanying text within UpToDate topic reviews of acquired long QT syndrome.</p>
<p>◊ Withdrawn from market in most countries due to adverse cardiovascular effects.</p>
<p>§ IV amisulpride antiemetic use is associated with less QTc prolongation than the higher doses administered orally as an antipsychotic.</p>
<p>¥ Some other cyclic antidepressants (ie, amoxapine, maprotiline, protriptyline, trimipramine) may also prolong the QT interval, but data are insufficient to identify level of risk with confidence; refer to UpToDate content on cyclic antidepressant pharmacology, administration, and side effects.</p>
<p>‡ The "low risk" category includes drugs with limited evidence of clinically significant QTc prolongation or TdP risk; many of these drugs have label warnings regarding possible QTc effects or recommendations to avoid use or increase ECG monitoring when combined with other QTc prolonging drugs.</p>
<p>† Rarely associated with significant QTc prolongation at usual doses for treatment of opioid use disorder, making buprenorphine a suitable alternative for patients with methadone-associated QTc prolongation. Refer to UpToDate clinical topic reviews.</p>
<p>** The United States FDA labeling for the sublingual preparation of dexmedetomidine warns against use in patients at elevated risk for QTc prolongation. Both intravenous (ie, sedative) and sublingual formulations of dexmedetomidine have a low risk of QTc prolongation and have <strong>not</strong> been implicated in TdP.</p>
<p>¶¶ Over-the-counter; available without a prescription.</p>
ΔΔ Not associated with significant QTc prolongation in healthy persons. Refer to UpToDate clinical topic for potential adverse cardiovascular (CV) effects in patients with CV disease.</div><div class="graphic_reference">Data from:
<ol>
<li>Lexicomp Online. Copyright ©1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
<li>CredibleMeds QT drugs list website sponsored by Science Foundation of the University of Arizona. Available at <a href="http://crediblemeds.org/" target="_blank">http://crediblemeds.org/</a>.</li>
</ol></div><div id="graphicVersion">Graphic 57431 Version 150.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
